Veeva Systems Inc. (VEEV) Stock Price & Analysis
Veeva Systems Inc. (VEEV) closed at USD 322.55 on Thursday, October 22, 2026, up 0.62% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 320.55; the Oct 22, 2026 session ranged USD 318.03–325.96 on volume of 1,435,403 shares. Market capitalization is $52.22B, with a 52-week range of USD 148.05–325.99 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VEEV.md
Key facts (VEEV)
- Last four reported quarters (through Jul 31, 2026): revenue $3.46B, net income $1.01B (29.3% margin) (SEC filings).
- Valuation: P/E 51.5x (avg 52.0x at the last 3 fiscal year-ends).
- 6 of 80 tracked superinvestors hold VEEV (13F, Q2 2026): 4 new, 1 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.10 on a 1–5 scale) (29 analysts), mean target USD 298.7 (range 180–360).
- Total return with dividends: 1Y +10.7% vs S&P 500 +14.9%; 5Y +0.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-25, EPS estimate USD 2.34, revenue estimate $935M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VEEV)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.85B | $2.16B | $2.36B | $2.75B | $3.20B | $3.46B |
| Gross profit | $1.35B | $1.55B | $1.69B | $2.05B | $2.41B | — |
| Operating income | $505M | $459M | $429M | $691M | $916M | $1.03B |
| Net income | $427M | $488M | $526M | $714M | $909M | $1.01B |
| EPS (diluted) | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 | — |
| Gross margin | 72.8% | 71.7% | 71.3% | 74.5% | 75.5% | — |
| Operating margin | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% | 29.9% |
| Net margin | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% | 29.3% |
| Revenue growth | +26.3% | +16.4% | +9.7% | +16.2% | +16.3% | — |
| Cash + short-term investments | $2.38B | $3.10B | $4.03B | $5.15B | $6.56B | — |
Fiscal years end Jan. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (VEEV)
P/E 51.5x · P/S 15.1x · P/B 7.0x · Earnings yield 1.94%
P/E at fiscal year-ends: Jan 2026 37.5x, Jan 2025 54.0x, Jan 2024 64.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (VEEV)
6 of 80 tracked investors hold VEEV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Jensen Investment Management | 1.93% | $79.8M | Reduced -20.6% | |
| Hillman Capital | Hillman Capital Management | 1.80% | $2.5M | New position |
| Terry Smith | Fundsmith | 1.06% | $145M | New position |
| Torray Funds | 0.59% | $4.4M | Added +3.6% | |
| Francois Rochon | Giverny Capital | 0.57% | $16.9M | New position |
| Vulcan Value Partners | 0.11% | $3.8M | New position |
Analysts (VEEV)
Consensus Buy (mean 2.10 on a 1–5 scale), 29 analysts; mean target USD 298.7 (low 180, high 360).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Barclays | Target raised | Overweight | $315 → $360 |
| 2026-08-28 | Citigroup | Target raised | Neutral | $190 → $273 |
| 2026-08-27 | Mizuho | Target raised | Outperform | $270 → $280 |
| 2026-08-27 | BMO Capital | Target raised | Market Perform | $175 → $270 |
| 2026-08-27 | Baird | Target raised | Outperform | $260 → $300 |
| 2026-08-27 | Canaccord Genuity | Target raised | Hold | $220 → $260 |
| 2026-08-27 | TD Cowen | Target raised | Buy | $235 → $283 |
| 2026-08-27 | Barclays | Target raised | Overweight | $275 → $315 |
| 2026-08-27 | UBS | Target raised | Neutral | $190 → $290 |
| 2026-08-27 | RBC Capital | Target raised | Outperform | $275 → $325 |
| 2026-08-27 | Guggenheim | Target raised | Buy | $276 → $310 |
| 2026-08-27 | Morgan Stanley | Target raised | Equal-Weight | $215 → $275 |
Total return (dividends reinvested) (VEEV)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +10.7% | +0.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +10.7% | +0.1% |
| Volatility (annualized) | 42.7% | 41.1% |
| Max drawdown | -49.4% (Nov 2025→Apr 2026) | -52.9% (Oct 2021→Oct 2022) |
VEEV revenue by product line (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Subscription | $766.8M | 82.6% | +16.3% |
| — R&D and Quality Solutions (part of Subscription) | $419.4M | 45.2% | +19.3% |
| — Commercial Solutions (part of Subscription) | $347.4M | 37.4% | +13.0% |
| Professional services and other | $161.2M | 17.4% | +24.1% |
| — R&D and Quality Solutions (part of Professional services and other) | $101.5M | 10.9% | +23.4% |
| — Commercial Solutions (part of Professional services and other) | $59.7M | 6.4% | +25.2% |
| Total revenue | $928.0M | 100% | — |
VEEV revenue by region (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $549.2M | 59.2% | +17.3% |
| Europe | $283.9M | 30.6% | +22.0% |
| Asia Pacific | $76.3M | 8.2% | +8.8% |
| Other international | $18.6M | 2.0% | +2.0% |
| Total revenue | $928.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
VEEV suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Amazon (AMZN) | “For our Veeva Vault applications, including Vault CRM, and certain other Veeva Commercial Cloud applications, we utilize Amazon Web Services.” |
| Supplier | Amazon Web Services and Salesforce | “We rely on third-party providers—including Amazon Web Services and Salesforce—for computing infrastructure, secure network connectivity, and other technology-related services needed to deliver our cloud solutions.” |
| Customer | Salesforce (CRM) | “Our customers may also choose to use cloud-based applications or platforms that are not life sciences specific—such as Salesforce, Box, Inc., Amazon Web Services, or Microsoft—for certain of the functions our applications provide.” |
| Customer | Box | “Our customers may also choose to use cloud-based applications or platforms that are not life sciences specific—such as Salesforce, Box, Inc., Amazon Web Services, or Microsoft—for certain of the functions our applications provide.” |
| Customer | Bayer | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Boehringer Ingelheim | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Eli Lilly (LLY) | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | GILEAD SCIENCES, INC. (GILD) | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Merck Sharp & Dohme | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Novartis Pharma | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Alkermes plc. (ALKS) | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Customer | Idorsia Pharmaceuticals | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| Partner | General | “A PBC is a for-profit company operating under subchapter XV of the General Corporation Law of the State of Delaware (i) that has adopted a public benefit purpose intended to provide benefits beyond just stockholder financial returns, and (ii) whose directors have a fiduciary duty to balance the financial interests of stockholders, the best interests of other stakeholders materially affected by the company's conduc…” |
| Partner | Zoom Video Communications | “For example, our Veeva CRM Engage Meeting application uses a purpose-built partner tool from Zoom Video Communications, Inc., which is critical to the application's functionality.” |
| Competitor | Oracle (ORCL) | “No single vendor offers products that compete with all of our Veeva Development Cloud or Quality Cloud applications, but IQVIA, Dassault Systèmes, OpenText Corporation, Oracle Corporation, Honeywell International Inc., and other smaller application providers offer applications that compete with certain of our Veeva Development Cloud and Quality Cloud applications.” |
| Competitor | Microsoft (MSFT) | “Our Commercial Cloud, Development Cloud, and Quality Cloud application suites also compete to replace client server-based legacy solutions offered by companies such as Oracle, Microsoft Corporation, and other smaller application providers.” |
| Competitor | Honeywell (HON) | “In this segment of our business, we compete with solutions such as those offered by OpenText, Microsoft, Honeywell, EtQ Management Consultants, LLC, Oracle, and Box, and custom-built software developed by third-party vendors or in-house by our potential customers.” |
Quoted from the company's 10-K filed Mar 20, 2026.
VEEV company outlook (results filed Aug 26, 2026)
- “Financial Outlook: Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows: • Total revenues between $932 and $935 million. • Non-GAAP operating income between $417 and $420 million.”
- “(2) Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows: • Total revenues between $3,682 and $3,687 million. • Non-GAAP operating income of about $1,640 million.”
Analysts expect $935.0M for the current quarter, in line with the midpoint of the company's guidance ($933.5M).
Quoted word-for-word from the SEC 8-K results press release.
VEEV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Oct 2026) | $2.34 | $2.29 | +2.5% | $935.0M | 26 |
| Next quarter (ends Jan 2027) | $2.31 | $2.32 | -0.4% | $944.0M | 26 |
| Current fiscal year (ends Jan 2027) | $9.24 | $9.06 | +1.9% | $3.69B | 27 |
| Next fiscal year (ends Jan 2028) | $10.25 | $10.03 | +2.2% | $4.14B | 26 |
VEEV options: expected move
Options price a move of about ±15.2% (±$49.10) by Dec 18, 2026, which includes earnings on Nov 25, 2026; the earnings reaction alone is priced at about ±5.1%. Over the last 8 reports the stock moved ±8.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 46.1% | ±10.4% |
| Dec 18, 2026 | 56 | 48.5% | ±15.2% |
| Jan 15, 2027 | 84 | 45.8% | ±17.5% |
| Mar 19, 2027 | 147 | 46.1% | ±23.2% |
| Jun 17, 2027 | 237 | 45.4% | ±29.0% |
| Sep 17, 2027 | 329 | 45.2% | ±33.8% |
30-day implied volatility 45% vs 28.7% realized over the last 30 trading days. Put/call ratio (volume) 0.87. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 322.55 |
|---|---|
| Change | ▲ 0.62% (up) |
| Previous Close | USD 320.55 |
| Open | USD 323.99 |
| Day Range | USD 318.03 – 325.96 |
| 52-Week Range | USD 148.05 – 325.99 |
| Volume | 1,435,403 shares |
| Market Cap | $52.22B |
| Exchange | NYQ |
Technical Analysis (VEEV)
Nexqual's technical model rates VEEV "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.32 (overbought) |
| vs SMA50 | Above (USD 275.52) |
| MACD | 14.27 (positive) |
Analyst Ratings (VEEV)
Wall Street analysts rate VEEV "Buy" based on 29 analysts, with a mean price target of USD 298.7 (range USD 180–360), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 298.7 |
| High Target | USD 360 |
| Low Target | USD 180 |
| Buy / Hold / Sell | 20 / 8 / 1 |
Earnings (VEEV)
| Next Earnings Date | 2026-11-25 |
|---|---|
| EPS Estimate | USD 2.34 |
| Revenue Estimate | $934.98M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD 2.35 vs est 2.22 ▲ beat |
| 2026-04-30 | USD 2.24 vs est 2.14 ▲ beat |
| 2026-01-31 | USD 2.06 vs est 1.94 ▲ beat |
| 2025-10-31 | USD 2.04 vs est 1.95 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (VEEV)
| Total Revenue | $3.46B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +17.60% |
| Gross Margin | +74.96% |
| Operating Margin | +29.64% |
| Profit Margin | +29.34% |
| ROE | +14.42% |
| Debt / Equity | 0.02 |
| Current Ratio | 5.46 |
| Total Cash | $7.24B |
| Total Debt | $151.70M |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (VEEV)
Nexqual rates Veeva Systems Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 30% (last 12 months) |
| Balance Sheet | Strong — $7.24B cash vs $152M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $1.42B (FY ended Jan 2026, 10-K) |
| Efficiency | Mixed — ROE 14%, ROA 7.6% |
Ownership (VEEV)
| Insider Ownership | +8.62% |
|---|---|
| Institutional Ownership | +93.24% |
| Shares Outstanding | 161.91M |
| Float | 148.29M |
| Short % of Float | +3.31% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (VEEV)
Veeva Systems Inc. is led by Peter P. Gassner, Founder, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| Founder, CEO & Director | Peter P. Gassner |
|---|---|
| President & Chief of Staff | Eleni Nitsa Zuppas |
| Chief Financial Officer | Brian Van Wagener |
| Director of Investor Relations | Gunnar Georg Hansen |
| Executive Vice President of Strategy & Campaign Manager | Paul Shawah |
Major Backers & Investors (VEEV)
Notable institutional backers of Veeva Systems Inc. include Principal Financial Group, Inc., Alliancebernstein L.P., Linonia Partnership LP, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Principal Financial Group, Inc. | 3.08% |
| Alliancebernstein L.P. | 3.03% |
| Linonia Partnership LP | 2.72% |
| AQR Capital Management, LLC | 2.16% |
| Price (T.Rowe) Associates Inc | 1.95% |
| Principal Funds, Inc-MidCap Fund | 1.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.57% |
| BlackRock | 7.94% |
| State Street | 4.14% |
| Geode Capital | 2.78% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Veeva Systems Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)
Key Strengths & Strategy (as disclosed to the SEC)
- For our Veeva Vault applications, including Vault CRM, and certain other Veeva Commercial Cloud applications, we utilize Amazon Web Services.
- Veeva Commercial Cloud includes solutions for the sales, marketing, and medical affairs functions of a life sciences company: •Veeva Vault CRM Suite is our next generation CRM solution built on our proprietary Veeva Vault platform.
- Despite our efforts to protect our proprietary technology and our intellectual property rights, unauthorized parties may attempt to copy or obtain and use our technology to develop applications with the same functionality as our application.
- Veeva Vault's unique ability to handle content and data allows us to build content and data-centric applications to help customers streamline end-to-end business processes and eliminate manual processes and siloed systems.
Legal & Regulatory Risks (Item 1A, quoted)
- We have been and may in the future be sued for infringement or misappropriation of third-party intellectual property. We may suffer damages, which could be significant, or other harm from these lawsuits.
- Our solutions address heavily regulated functions within the life sciences industry, and failure to comply with applicable laws and regulations could lessen the demand for our solutions or subject us to significant claims and losses.
- Our status as a Delaware public benefit corporation may not result in the benefits that we anticipate, requires our directors to balance the interest of stockholders with other interests, and may subject us to legal uncertainty and other risks.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BTSG | BrightSpring Health Services, I | USD 60.86 | ▼ 2.41% |
| TEM | Tempus AI, Inc. | USD 63.81 | ▼ 5.83% |
| HNGE | Hinge Health, Inc. | USD 109.93 | ▼ 1.85% |
| HQY | HealthEquity, Inc. | USD 100.97 | ▲ 3.16% |
| DOCS | Doximity, Inc. | USD 33.68 | ▲ 0.3% |
| WAY | Waystar Holding Corp. | USD 28.98 | ▲ 0.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt